Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

Strengthening ties with Belgium ally
2013-10-31

 

From the left are: Prof Dr Johan Meeusen signing the agreement with Prof Nicky Morgan, Vice-Rector: Operations.
Photo: Hannes Pieterse
31 October 2013

The UFS signed a formal agreement with the University of Antwerp, strengthening the two institutions’ existing collaboration. Prof Dr Johan Meeusen, Vice-Rector and Professor of European Law and Private International Law at the University of Antwerp, visited the Bloemfontein Campus to sign the agreement. This arrangement will ensure that the two institutions work in close conjunction on research and additional projects.

Dineo Gaofhiwe-Ingram, Assistant Director: Internationalisation, says the new relationship between the two universities will have a strong research focus. "It’s evident and known that we want to become a research-intensive university.” She emphasises that the relationship with Antwerp as well as partnerships with a variety of other institutions are crucial. These will ensure that young emerging scholars, like those taking part in the Vice-Chancellor's Prestige Scholars Programme, are exposed internationally during their development. “We hope that some of the scholars in the new cohort of the PSP will be able to find scientists to host them at Antwerp," Gaofhiwe-Ingram adds.

In addition, she explains that this formal agreement will augment pre-existing collaborations with the Unit for Language Facilitation and Empowerment, as well as the Centre for Health Systems Research and Development. It will also open up cooperation between other faculties and disciplines. “Through Eurosa/Erasmus Mundus Project, which awards scholarships to South African students and staff to study in Europe, the 2014 project will now also award scholarships to European students and staff to come and study in South Africa,” Gaofhiwe-Ingram announced.

The University of Antwerp is one of the European associates that participates in the Leadership for Change Programme and hosted a group of first-year Kovsie students during 2011. In 2012, representatives from the University of Antwerp attended the Leadership Summit presented on the Bloemfontein Campus. Another group of first-year students from the UFS took part in this year’s programme.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept